|
|
Article: FDA Approves SINGULAIR For Seasonal Allergic Rhinitis; A New Class of Therapy for the Treatment of Seasonal Allergic Rhinitis -Also Known as Hay Fever-.
- Article from:
- Business Wire
- Article date:
- January 2, 2003
CopyrightCOPYRIGHT 2003 Business Wire. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Business Editors/Health & Pharmaceutical Writers
NOTE TO MEDIA: Multimedia assets available
A photo is available at URL:
http://www.businesswire.com/cgi-bin/photo.cgi?pw.010203/bb3
WHITEHOUSE STATION, N.J.--(BUSINESS WIRE)--Jan. 2, 2003
Merck & Co., Inc. announced today that the U.S. Food and Drug Administration (FDA) has approved the leukotriene blocker SINGULAIR(R) (montelukast sodium) for the relief of symptoms of seasonal allergic rhinitis (also known as hay fever).
A convenient once-a-day tablet, SINGULAIR helps relieve a broad range of seasonal allergy symptoms for 24 hours. SINGULAIR is available to treat ...